MENUNews Archive
Date: 06/20/2022
Scientists have been working to make a mouse model of this tumor to better understand the disease biology to support preclinical testing of novel drugs, but no one before has been successful. A Merkel cell polyomavirus is believed to cause about 80% of these tumors, but researchers have been unable to definitively show this in vivo.
Date: 06/07/2022
A study published in Nature Communications, led by Imad Shureiqi, M.D., shows that, pre-cancerous pancreatic lesions in mice, similar to those found in humans, contain higher levels of the transcriptional receptor peroxisome proliferator activated receptor-delta (PPARδ).
Date: 06/03/2022
Scientists at the University of Michigan Rogel Cancer Center were optimistic when they identified a small molecule that blocked a key pathway in brain tumors. But there was a problem: How to get the inhibitor through the bloodstream and into the brain to reach the tumor. In collaboration with multiple labs, the teams fabricated a nanoparticle to contain the inhibitor, and the results were even better than expected.
Date: 05/26/2022
More than 30 Rogel Cancer Center-led research efforts will be presented during the 2022 ASCO Annual Meeting, running June 3-7 at McCormick Place in Chicago, Illinois, and online.
Date: 05/26/2022
Men with advanced prostate cancer taking abiraterone or enzalutamide plus hormone therapy were at higher risk of serious medical issues than their peers undergoing hormone therapy alone.
Date: 05/20/2022
The Rogel Cancer Center has recently appointed four faculty members to named professorships. A named professorship is the highest honor a department or center can bestow upon a faculty member. Professorships are made possible by the generosity of donors.
Date: 05/16/2022
In early research led by the University of Michigan Health Rogel Cancer Center, the oral medication zanubrutinib was found to help most patients with a slow-growing type of cancer known as marginal zone lymphoma. Cancers shrunk in 80% of the 20 patients on the clinical trial with marginal zone lymphoma, with a fifth experiencing complete remission.
Date: 05/02/2022
In mice, nanomedicine can remodel the immune microenvironment in lymph node and tumor tissue for long-term remission and lung tumor elimination in this form of metastasized breast cancer.
Date: 04/28/2022
The University of Michigan Rogel Cancer Center will provide funding support to 12 exceptional faculty researchers, 2 early career clinical researchers and six medical and graduate students. In addition, the center has launched a new program for Rogel Scholars in Cancer Health Equity, to support two faculty members who are working to address the cancer burden in historically underserved or excluded populations.
Date: 04/25/2022
By using an artificial intelligence-based system, researchers improved doctors' assessment of whether patients with bladder cancer had a complete response to chemotherapy before undergoing a radical cystectomy (bladder cancer removal surgery).